The IBD Clinic: Continuity of Care in IBD - From Diagnosis to Management


The IBD Clinic: Continuity of Care in IBD - From Diagnosis to Management

Topic: Gastroenterology
Relevant Terms: IBD Management
Primary Audience: Gastroenterologists and Gastroenterology Clinicians
Launch Date: 02-Feb-17
Credits: 0.75 AMA PRA Category 1 Credit
Expiration Date: The accreditation for this activity has expired.
Curriculum Name: The Gastroenterology Learning Pathway

Learning Objectives

After completing this activity, the participant will demonstrate the ability to:

  1. Compare and contrast the clinical effects of IBD therapies
  2. Select individualized treatments for patients with IBD that maximize the opportunity to achieve remission and avoid relapse while minimizing toxicity
  3. Utilize available disease progression and drug monitoring strategies for patients with IBD
  4. Implement American Gastroenterological Association (AGA) practice measures in managing patients with IBD


    Adam S. Cheifetz, MD
    Director, Center for Inflammatory Bowel Disease
    Beth Israel Deaconess Medical Center
    Associate Professor of Medicine
    Harvard Medical School
    Boston, MA
    Uma Mahadevan, MD
    Professor of Medicine
    University of California, San Francisco
    Co-Medical Director
    UCSF Center for Colitis and Crohn's Disease
    San Francisco, CA
    David A. Schwartz, MD, FACG, AGAF
    Professor of Medicine
    Director, Inflammatory Bowel Disease Center
    Vanderbilt University Medical Center
    Nashville, TN
    Robin Dalal, MD 
    Gastroenterology Fellow
    Vanderbilt University Medical Center
    Nashville, TN
    The American Gastroenterological Association (AGA) Institute is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
    The AGA Institute designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
    In accordance with the ACCME’s Standards for Commercial Support of Continuing Medical Education, all faculty and planning partners must disclose any financial relationship(s) or other relationship(s) held within the past 12 months. The AGA Institute implements a mechanism to identify and resolve all conflicts of interest prior to delivering the educational activity to learners.

    The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
    • Adam Cheifetz, MD, has affiliations with Consulting: AbbVie, Pfizer, Samsung, Takeda.
    • Uma Mahadevan, MD, has affiliations with Consulting: AbbVie, Celgene, Janssen, Pfizer, Takeda, UCB Pharma; Grant Support: Prometheus Laboratories.
    • David Schwartz, MD, has affiliations with Consulting: AbbVie, Janssen, Takeda, Tigenix, UCB Pharma; Grant Support: AbbVie, UCB Pharma.
    • Robin Dalal, MD, has no affiliations with commercial interests to disclose.
    RMEI Medical Education, LLC
    • Jacqui Brooks, MBBCh, MRCPsych, has no affiliations with commercial interests to disclose.
    • Tania Dickson, PhD, has no affiliations with commercial interests to disclose.
    • Amy Reeve has no affiliations with commercial interests to disclose.
    • Nora Hartley has no affiliations with commercial interests to disclose.
    AGA Institute
    • Sandra Megally Amos has no affiliations with commercial interests to disclose.
    • Maura H. Davis has no affiliations with commercial interests to disclose.
    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients' conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
    This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. 
    The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
    Estimated time to complete: 0.75 hours
    Medium: Internet

    There is no fee for this educational activity.

    This activity is supported by independent educational grants from AbbVie, Shire, and Takeda Pharmaceuticals, USA, Inc.

    By reviewing the course content and successfully completing the activity, physicians, nurse practitioners, and physician assistants are entitled to receive up to 0.75 AMA PRA Category 1 Credit(s)™. A statement of credit will be available to print from your user history page. Users must:
    • Read the learning objectives and faculty disclosures.
    • Participate in the activity.
    • Complete the activity evaluation.
    Physicians, nurse practitioners, and physician assistants who successfully complete the self-assessment questions and evaluation will receive CME credit. You must score 75% or higher on the self-assessment test to receive credit for this activity. All other participants who successfully complete the activity and evaluation will receive a certificate of participation.
    Supported Browsers:
    Internet Explorer 9.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1
    Google Chrome 28.0+ for Windows, Mac OS, or Linux
    Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
    Safari 6.0+ for Mac OSX 10.7 and above